The purpose of this study is to assess the abuse liability and examine the reinforcing
effects of intravenous buprenorphine and buprenorphine/naloxone combinations in
buprenorphine-naloxone maintained volunteers
Ongoing study - results not available at this time
Individuals must be at least 18 yrs of age, currently opioid dependent and meet FDA
criteria for narcotic maintenance treatment. Co-morbid substance abuse or dependence
disorders may also be present. Individuals must be healthy despite drug dependency and
have a history of IV opioid use.
Individuals with evidence of anti active Diagnostic and Statistical Manual of Mental
Disorders (DSM-IV) Axis I psychiatric disorder (e.g. psychosis, manic-depressive illness,
organic psychiatric disorders), significant medical illness (e.g. liver or cardiovascular
disease) or pregnant female subjects are excluded from study participation.